ES3027507T3 - Method to use gene expression to determine likelihood of clinical outcome of renal cancer - Google Patents

Method to use gene expression to determine likelihood of clinical outcome of renal cancer Download PDF

Info

Publication number
ES3027507T3
ES3027507T3 ES20210111T ES20210111T ES3027507T3 ES 3027507 T3 ES3027507 T3 ES 3027507T3 ES 20210111 T ES20210111 T ES 20210111T ES 20210111 T ES20210111 T ES 20210111T ES 3027507 T3 ES3027507 T3 ES 3027507T3
Authority
ES
Spain
Prior art keywords
expression
genes
gene
rna
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20210111T
Other languages
English (en)
Spanish (es)
Inventor
Steven Shak
Audrey Goddard
Dejan Knezevic
Joffre B Baker
Michael C Kiefer
Tara Maddala
Frederick L Baehner
Wayne Cowens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of ES3027507T3 publication Critical patent/ES3027507T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57525—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Computing Systems (AREA)
  • Artificial Intelligence (AREA)
  • Mathematical Physics (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
ES20210111T 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer Active ES3027507T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19

Publications (1)

Publication Number Publication Date
ES3027507T3 true ES3027507T3 (en) 2025-06-16

Family

ID=44258831

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20210111T Active ES3027507T3 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
ES17153152T Active ES2741379T3 (es) 2010-01-11 2011-01-07 Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17153152T Active ES2741379T3 (es) 2010-01-11 2011-01-07 Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal

Country Status (12)

Country Link
US (4) US9551034B2 (show.php)
EP (5) EP3831964B1 (show.php)
JP (5) JP6286124B2 (show.php)
AU (1) AU2011203977B2 (show.php)
CA (3) CA3128103C (show.php)
DK (1) DK3178944T3 (show.php)
ES (2) ES3027507T3 (show.php)
IL (6) IL219978A (show.php)
MX (3) MX341866B (show.php)
NZ (4) NZ719474A (show.php)
SG (1) SG181806A1 (show.php)
WO (1) WO2011085263A2 (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3831964B1 (en) 2010-01-11 2025-04-16 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX359416B (es) 2010-07-27 2018-09-27 Genomic Health Inc Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
BR112013003391B8 (pt) 2010-08-13 2022-10-25 Somalogic Inc Método para diagnosticar câncer pancreático em um indivíduo
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
CA2843756A1 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
JP6259764B2 (ja) 2011-10-24 2018-01-10 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 炭酸脱水酵素関連マーカーおよびその使用
EP2809812A4 (en) 2012-01-31 2016-01-27 Genomic Health Inc GENE EXPRESSION PROFILE ALGORITHM AND PROSTATE CANCER PROGNOSTIC DETERMINATION TEST
AU2014274135B2 (en) * 2013-05-30 2020-04-09 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
WO2020033866A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
RU2747746C2 (ru) * 2018-10-24 2021-05-13 Общество с ограниченной ответственностью «Онкобокс» Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US20220364178A1 (en) * 2019-08-14 2022-11-17 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
CA3210480A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
EP1246917B1 (en) * 2000-01-13 2009-03-04 Genentech, Inc. Human stra6 polypeptides
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2442820A1 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
EP1570078A4 (en) 2002-10-04 2006-09-13 Van Andel Res Inst MOLECULAR CLASSIFICATION OF RENAL TUMORS AND DISCOVERING NEW DIAGNOSTIC MARKERS
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
EP1618218A2 (en) 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors
ES2690168T3 (es) 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
AU2004256182A1 (en) 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US20050130193A1 (en) 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
EP1766091A4 (en) * 2004-05-27 2009-03-18 Vertex Pharma BIOMARKER FOR MONITORING THE INHIBITION OF THE IMPDH PATH
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
EP1846576A4 (en) * 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKERS OF TISSUE STATUS
RU2007129864A (ru) * 2005-02-18 2009-03-27 Вайет (Us) Фармакогеномные маркеры для прогнозирования солидных опухолей
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) * 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE456557T1 (de) 2005-06-15 2010-02-15 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
EP1930426A4 (en) 2005-09-02 2009-04-29 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING KIDNEY CANCER AND ASSESSING THE PROGNOSIS OF A KIDNEY CANCER PATIENTS
ATE531820T1 (de) 2005-09-14 2011-11-15 Human Genetic Signatures Pty Gesundheitszustandstest
CA2622852A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP2009523709A (ja) 2005-12-16 2009-06-25 ジェネンテック・インコーポレーテッド 神経膠腫の診断、予後の予測及び治療の方法
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
EP2046973A4 (en) 2006-08-10 2010-04-07 Millennium Pharm Inc IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCER THERAPY PATIENTS
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
EP3831954A3 (en) 2008-11-17 2021-10-13 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
AU2010264763B2 (en) * 2009-06-26 2015-07-23 Noviogendix Research B.V. Molecular markers in kidney cancer
NZ599194A (en) 2009-11-23 2014-07-25 Genomic Health Inc Methods to predict clinical outcome of cancer
EP3831964B1 (en) 2010-01-11 2025-04-16 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CN103797131A (zh) 2011-06-16 2014-05-14 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
CA2843756A1 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
SG181806A1 (en) 2012-07-30
MX375138B (es) 2025-03-06
JP6546214B2 (ja) 2019-07-17
US20210166790A1 (en) 2021-06-03
IL262100A (en) 2018-11-29
NZ705645A (en) 2016-05-27
ES2741379T3 (es) 2020-02-10
EP3178944A3 (en) 2017-09-13
IL251635B (en) 2018-04-30
EP2524055A4 (en) 2013-06-05
IL219978A (en) 2017-04-30
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
CA3256492A1 (en) 2025-11-29
EP2524055A2 (en) 2012-11-21
IL262100B (en) 2019-11-28
DK3178944T3 (da) 2019-08-12
NZ600268A (en) 2014-08-29
US10892038B2 (en) 2021-01-12
US11776664B2 (en) 2023-10-03
JP6286124B2 (ja) 2018-02-28
US20220051755A9 (en) 2022-02-17
US20110171633A1 (en) 2011-07-14
US12412642B2 (en) 2025-09-09
JP2019162150A (ja) 2019-09-26
IL280689A (en) 2021-03-25
CA2783858C (en) 2021-09-14
WO2011085263A3 (en) 2012-01-12
CA3128103C (en) 2025-11-18
US9551034B2 (en) 2017-01-24
EP3831964A2 (en) 2021-06-09
IL219978A0 (en) 2012-07-31
US20170121780A1 (en) 2017-05-04
EP3029155A2 (en) 2016-06-08
JP2013516195A (ja) 2013-05-13
US20240096451A1 (en) 2024-03-21
WO2011085263A2 (en) 2011-07-14
AU2011203977B2 (en) 2015-02-05
EP3831964B1 (en) 2025-04-16
JP7307602B2 (ja) 2023-07-12
JP2016174600A (ja) 2016-10-06
EP3029155A3 (en) 2016-08-31
MX341866B (es) 2016-09-06
MX2020009704A (es) 2020-10-07
NZ719474A (en) 2018-07-27
MX2012007882A (es) 2012-08-03
AU2011203977A1 (en) 2012-06-21
EP3561078A1 (en) 2019-10-30
IL256335B (en) 2018-12-31
IL280689B (en) 2022-01-01
JP2021177761A (ja) 2021-11-18
CA2783858A1 (en) 2011-07-14
IL270151B (en) 2021-03-25
CA3128103A1 (en) 2011-07-14
EP3831964A3 (en) 2021-10-20
NZ617003A (en) 2015-04-24
JP7385630B2 (ja) 2023-11-22
IL251635A0 (en) 2017-06-29
JP2017148059A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
JP7385630B2 (ja) 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP5297202B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
ES2735993T3 (es) Métodos para predecir el resultado clínico del cáncer
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2016118670A1 (en) Multigene expression assay for patient stratification in resected colorectal liver metastases
ES2914727T3 (es) Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer